Novel physicochemical approach to optical biosensing that leverages the unique properties of 1DZnO nanostructures. These ...

BofA Securities, TD Cowen, Stifel, Cantor and William Blair are acting as joint book-running managers for the offering. Wedbush PacGrow, LifeSci Capital, BTIG and Jones are acting as co-managers for ...

Phase 1 dose escalation is complete, establishing safety and proof of mechanism. Coherus plans to: Report Phase 1 monotherapy biopsy data as well as CHS-114/toripalimab combination safety data in head ...

Clinical-stage life sciences company Invion (ASX: IVX) has dosed the first patient in its Phase I/II non-melanoma skin cancer ...

The FDA has approved 43 novel drugs so far this year (January-November), compared to 52 during the same period last year. As we step ...

With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...

At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...

It’s hard not to reminisce about Christmases past and have thoughts of thanksgiving during this special time of year. Paula ...

Dr. Harb urges annual lung checks for smokers, highlighting the importance of early lung cancer detection through low-dose ...

Check out our weekly list of new fundraisers from Lend A Hand Up, a nonprofit crowdfunding site supporting families in Cass, ...

China’s NRDL includes Akeso’s two bispecific antibody drugs, cadonilimab & ivonescimab: Hong Kong Friday, November 29, 2024, 10:00 Hrs [IST] Akeso, Inc., a leading biopharmace ...